Boehringer Ingelheim’s Praxbind deemed eligible for reimbursement

Boehringer Ingelheim has announced that its anticoagulant reversal agent Praxbind is now available to be used commercially in England, Ireland and Wales.

The Health Technology Appraisal bodies in all three countries have agreed Praxbind should be made eligible for full reimbursement without the need for a full appraisal, following on from its European Commission approval in November 2015.

Praxbind was developed to rapidly and specifically reverse the anticoagulant effect of Boehringer Ingelheim's own Pradaxa among patients needing emergency surgery, or who are in situations of life-threatening or uncontrolled bleeding.

It is the first and only specific reversal agent for a novel oral anticoagulant to be granted a licence in the EU, and its availability will allow Pradaxa to be used more safely and with greater confidence in future.

Professor Klaus Dugi, medical director and managing director for Boehringer Ingelheim in the UK and Ireland, said: "While we do not anticipate that it will be used regularly, there can be no doubt that its availability will provide added confidence for prescribers when choosing dabigatran for their patients."